Information Hub

Clinical News

2018-10-01

Niraparib Shows Promise in Recurrent Ovarian Cancer with homologous recombinant deficiency

In the phase 2 QUADRA study, niraparib showed durable antitumor activity in patients with advanced, relapsed, high-grade serous epithelial ovarian cancer.

Source:

Journal of Clinical Oncology

2018-10-01

STK11/LKB1 Mutations Confer Resistance to Immune checkpoint inhibitors in NSCLC

In two recently published studies, immune checkpoint inhibitors showed inferior clinical outcome in NSCLC patients carrying STK11 mutations

Source:

Cancer Discov & J Clin Oncol

2018-10-01

Refametinib/Sorafenib Combo Improves Survival in RAS-Mutated hepatocellular carcinoma

Two phase 2 studies showed that the combination of refametinib and sorafenib improved overall survival (OS) and objective response rate (ORR) in patients with RAS-mutated hepatocellular carcinoma (HCC)

Source:

Clin Cancer Res

2018-10-01

Capmatinib plus Gefitinib Is Active in MET-dysregulated NSCLC

A phase Ib/II study shows that the combination of capmatinib with gefitinib is a promising treatment for patients with EGFR-mutated, MET-dysregulated NSCLC

Source:

J Clin Oncol

2018-10-01

Genome editing tool helps make classification of BRCA1 variants more accurate

Researchers in the University of Washington applied genome editing to measure nearly 4000 single-nucleotide variants (SNVs) in 13 exons that are associated with BRCA1 functional domains. They identified more than 400 missense variants that would make BRCA

Source:

Nature

2018-08-31

FDA approves the combination of Nivolumab (Opdivo) and Ipilimumab (Yervoy) for MSI-H/dMMR Colorectal Cancer

The U.S. FDA approves nivolumab and ipilimumab in combination for patients with MSI-H/dMMR colorectal cancer based on the phase II CheckMate-142 study.

Source:

J Clin Oncol

2018-08-31

FDA grants a breakthrough therapy designation to the combination of the BRAF inhibitor encorafenib (Braftovi), the MEK inhibitor binimetinib (Mektovi), and the EGFR inhibitor cetuximab (Erbitux) for BRAF-mutant Colorectal Cancer

FDA grants a breakthrough therapy designation to the combination of encorafenib plus binimetinib and cetuximab for BRAF-mutant colorectal cancer following the failure of one or two prior lines of therapy.

Source:

Annals of Oncology

2018-08-31

FDA Grants Breakthrough Status to Lenvatinib/Pembrolizumab for Endometrial Cancer

The FDA has granted a breakthrough therapy designation to the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced and/or metastatic non–microsatellite instability high (MSI-H)/proficient mismatch repair (pMMR) endometri

Source:

J Clin Oncol

2018-08-31

FDA Grants Quizartinib Breakthrough Designation for FLT3-ITD+ acute myeloid leukemia

The FDA has granted a breakthrough therapy designation to quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia (AML)

Source:

2018 EHA Congress

2018-08-31

People with germline BARD1, BRCA1/2, PALB2 and RAD51D pathogenic mutations have an increased risk of triple-negative breast cancer

Researchers in Mayo clinic included 10901 TNBC patients and evaluated their germline genetic testing results of 21 hereditary cancer genes. From the statistical analysis, in addition to BRCA1, pathogenic variants in BARD1, BRCA2, PALB2 and RAD51D also inc

Source:

J Natl Cancer Inst